The Aquatic Animal Drug Approval Partnership (AADAP) Program, as it functions today, actually had its genesis in the early 1990’s. In direct response to an “announcement” by the U.S. Food and Drug Administration (FDA) in 1991 that the time had finally arrived when drug and therapeutant use in aquaculture needed to be regulated, the U.S. Fish and Wildlife Service (Service), as well as many others, discontinued the use of unapproved drugs and therapeutants in fisheries programs, and engaged in the compassionate Investigational New Animal Drug (INAD) exemption process. This announcement was a “pretty hard hit” for all concerned. Prior to this development, fisheries managers’ access to needed drugs, chemicals, and therapeutants to maintain fish health and manage production programs was limited only by one’s imagination and/or access at a chemical supply company or the local Ranch N’ Home store. This situation was further exacerbated by the fact that only three therapeutants and a single anesthetic were actually approved for use in aquatic species, and use of these compounds was severely restricted by species, water temperature, and life-stage. Although compassionate INAD exemptions did allow for the continued use of certain unapproved drugs in an approved-manner (i.e., under strict FDA guidelines), fish culture had changed forever.
Induction, Recovery, and Hematological Responses of Pallid Sturgeon to Chemical and Electrical Sedation
Currently, there are no U.S. Food and Drug Administration-approved sedatives available to fisheries professionals that are considered effective, safe to a broad range of fish species, practical to use, and allow sedated fish to be returned to public waters immediately upon recovery. As such, we conducted an experiment to quantitatively compare induction and recovery times of Pallid Sturgeon sedated using tricaine methanesulfonate (MS-222), eugenol, or electrosedation (pulsed DC). Our results showed that the electrosedation protocol and chemical sedative doses tested effectively sedated Pallid Sturgeon, that all individuals sedated recovered, and there was no delayed mortality associated with sedation.
Efficacy of Chloramine-T to Control Mortality in Tiger Musky Esox lucius × E. masquinongy Naturally Infected with External Columnaris Disease Flavobacerium columnare
DRIB #46 was recently "published" on this website and summarizes a study to evaluate the efficacy of chloramine-T to control mortality in Tiger Musky infected with columnaris disease. The study was conducted in 2014 in cooperation with staff at the New York Department of Environmental Conservation S. Otselic Hatchery in South Otselic, NY. At the end of the study, mean % cumulative mortality (13%) in tanks treated with 20 mg/L chloramine-T for 60 min on three consecutive days was significantly different than that in control tanks (82%). Results from this study will be used by the sponsor to expand the US Food and Drug Administration approval to include use to control mortality in all freshwater-reared cool- and warmwater finfish caused by columnaris disease.
Recap - 22nd Annual USFWS Aquatic Animal Drug Coordination Workshop
The 22nd Annual Aquaculture Drug Approval Coordination Workshop (Workshop) was held at the Snow King Lodge in Jackson WY on June 9-10, 2016. The Workshop was held in conjunction with the 57th Western Fish Disease Workshop and American Fisheries Society Fish Health Section Executive Committee and Business Meetings. The Workshop was hosted for the 19th time by the U. S. Fish and Wildlife Service (FWS) Aquatic Animal Drug Approval Partnership (AADAP) Program - and is now commonly referred to as the AADAP Workshop.
"Why INADs are a fish farmer's best friend" by Rod Getchell
Aquaculture Drug Approval Coordination Workshop where AADAP's own Bonnie Johnson presented 15 years worth of INAD data to the audience. Rod was so impressed with the INAD activity that he wrote the following article that is in the Fish Farming News under the Fish Health Notes section. "Fish farmers can use Investigational New Animal Drug (INAD) exemptions to medicate their fish with certain drugs that have not yet been approved for use, as long as they follow use-guidelines and collect data that can contribute to the eventual approval of the drug." Click on the following link to continue reading the rest of Rod's article.